Scarica l'app Stockscreener
17.96
0.11%
-0.0135
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView
AMLX Forecast — Price Target — Prediction for 2027 - TradingView
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa
AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa
Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - BioSpace
Amylyx presents early safety data for ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria
Amylyx presents early safety data for ALS drug candidate AMX0114 - Investing.com
Amylyx says ALS drug AMX0114 showed no serious safety issues - Stock Titan
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen - Moomoo
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR - Moomoo
Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amylyx Pharmaceuticals eyes Q3 phase 3 Avexitide readout as PBH launch plans take shape - MSN
How Amylyx’s Class Action Settlement and Phase 3 Avexitide Milestone At Amylyx Pharmaceuticals (AMLX) Has Changed Its Investment Story - simplywall.st
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace
Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan
Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan
Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan
Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan
Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan
Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot
0.67%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):